Zymo Research’s Saliva Self-Collection & Transport Device Gets FDA Clearance
The FDA cleared Zymo Research's DNA/RNA Shield SafeCollect Saliva Collection Kit for microbial nucleic acid storage and stabilization.
The FDA cleared Zymo Research's DNA/RNA Shield SafeCollect Saliva Collection Kit for microbial nucleic acid storage and stabilization.
Dried blood spot testing provides clinical labs an easy-to-collect, reliable, and cost-effective means to test for a variety of diseases.
The self-contained saliva collection kit provides sample consistency while suspending and neutralizing viral RNA transcripts, completely inactivating the live covid-19 virus.
The immunoblot tests represent a quantum leap in testing for tick-borne diseases, particularly for patients with Lyme-like symptoms.
Read MoreIn studies of primary progressive and relapsing multiple sclerosis, blood neurofilament light chain levels were significantly lower following treatment with Ocrevus.
Read MoreClearLight will combine the new Crystal technology with its Clarity automated lipid-clearing platform.
Read MoreThe study will evaluate the utility of Elypta’s liquid biopsy platform for the early detection of recurrence in renal cell carcinoma patients after surgery.
Read MoreThe study results point to the value of liquid biopsies as a noninvasive approach to genotyping and monitoring in patients diagnosed with advanced forms of cancer.
Read MoreUniform tissue storage products enable biobanks to standardize and automate the handling and storage of tissue samples in the same way as liquid samples.
Read MoreAutomated volume reduction increases precision and accuracy in rare-cell workflows.
Read MoreThe test reduces the need for invasive tissue biopsies.
Read MoreThe TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.
Read MoreThe test helps clinicians to determine whether a patient with metastatic castration-resistant prostate cancer will benefit most from taxane chemotherapy or androgen-directed therapeutics.
Read MoreCertification of the Elio Plasma Resolve liquid biopsy panel will make available a local, noninvasive, next-generation sequencing solution in Europe.
Read MoreThe liquid biopsy may enable clinical researchers to better understand tumor biology, particularly in early-stage disease.
Read MoreUsing the kit, clinicians can accurately and reproducibly monitor residual disease in patients with chronic myeloid leukemia, even at low levels.
Read MoreTogether, Precipio and PerkinElmer can provide a simple, reliable, automated cell-free DNA analysis workflow alongside a cutting-edge mutation enrichment technology, ICE COLD PCR, that will enable laboratories to efficiently use these technologies to support liquid biopsy testing.
Read MoreWith three NCI grants, BioFluidica is investigating chip-based liquid biopsy technologies for the detection of cancer and related genetic variants.
Read More